Biophysical chemistry

B&C and Acta Announce Appointment of Mark J. Washko as Senior Government Affairs Advisor, and Alexander E. Howard and Michelle C. Mims to Science Team Positions

Retrieved on: 
Friday, March 1, 2024
National Association, Reno 1868 FC, Commerce, Molecular biology, Consultant, University, ASTM, House, Biophysical chemistry, Energy, EPA, Legislation, Public policy, Representative, Good laboratory practice, Advisory board, Committee, Environmental justice, Federation, College, Bowling Green State University, Quality assurance, Corteva, Majority, Biophysical environment, BASF, Environment, OECD, Business network, TSCA, Sunscreen Innovation Act, Charles River Laboratories, Government, Organization, GLP, Frank, Bachelor, Society, B&C, Policy, American Chemistry Council, Management

WASHINGTON, March 1, 2024 /PRNewswire-PRWeb/ -- Bergeson & Campbell, P.C. (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of several professionals to key roles at our firms.

Key Points: 
  • (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of Mark J. Washko, Alexander E. Howard, and Michelle C. Mims to key roles at our firms.
  • (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of several professionals to key roles at our firms.
  • Mr. Washko, Mr. Howard, and Ms. Mims join a powerful team of advocates, scientists, and regulatory and business consultants at B&C and Acta.
  • Mr. Washko, Mr. Howard, and Ms. Mims join a powerful team of advocates, scientists, and regulatory and business consultants at B&C and Acta.

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Retrieved on: 
Wednesday, February 7, 2024
ARD International Music Competition, Growth, Wesleyan University, Biophysical chemistry, Chairperson, Harvard University, DLB, Caregiver, Medicinal chemistry, Patient, Laboratory, CRVO, Vertex Pharmaceuticals, Philosophy, Inflammation, Drug design, Doctorate, Brain, Immunology, Drug development, Merck, Lewy body, Merck & Co., Dementia, Master, Pharmaceutical industry

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical company leadership experience to CervoMed as it progresses toward an important inflection point. Topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) is expected in the second half of 2024. The Board Chair position was formerly held by CervoMed co-founder Dr. Sylvie Gregoire, who will continue to serve as a director.

Key Points: 
  • The Board Chair position was formerly held by CervoMed co-founder Dr. Sylvie Gregoire, who will continue to serve as a director.
  • “It is a pleasure to welcome Joshua, the founder of Vertex and an esteemed industry leader, to our Board of Directors,” said John Alam, M.D., Chief Executive Officer of CervoMed.
  • Dr. Joshua Boger is an industry veteran who has served in multiple scientific and business leadership roles in his 40+ year career.
  • He continued to serve on the Vertex Board and Chair Vertex’s Science & Technology Committee until 2017.

iXCells Biotechnologies Strengthens Leadership Team; Welcomes New CEO

Retrieved on: 
Thursday, January 18, 2024
Research, Infectious Diseases, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Columbia Business School, Patient, University, Molecular diagnostics, IPSC, Biophysical chemistry, Sigma-Aldrich, SGS, Thermo Fisher Scientific, B cell, Business development, Executive, Disease, Drug development, QIAGEN, University of Göttingen, Doctor of Philosophy, Genome, Synthetic biology, Alumni, RUO, Nobel Prize, Growth, Management

To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team.

Key Points: 
  • To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team.
  • Helge brings to iXCells a wealth of entrepreneurial and intrapreneurial leadership experience across the life sciences and healthcare space in building businesses for small and large companies with a proven track record of value creation.
  • In addition, Dr. Bastian led oncology focused Indivumed and M2GEN (now Aster Insights) as Managing Director & Chief Commercial Officer and CEO, respectively.
  • Dr. Lynn Zhang will continue to serve on iXCells’ board of directors and assist with transitioning CEO leadership responsibilities in the coming months.

Dr. Carl Barrett Joins Corista as Chief Life Sciences Officer

Retrieved on: 
Tuesday, September 26, 2023
Computational biology, CCR, Informatics, University, College, Pathology, Research, Genomics, University of North Carolina at Charlotte, Biomarker, Proteomics, History of the College of William & Mary, Translational medicine, Biophysical chemistry, Johns Hopkins University, Japanese Cancer Association, Physician, Cancer, AstraZeneca, AI, Book, Management, Pharmaceutical industry, Medical imaging, Dentistry

CONCORD, Mass., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Dr. Carl Barrett steps into a new role as Chief Life Sciences Officer at Corista, a leader in digital image management solutions. This new leadership position, with Dr. Barrett's appointment, continue Corista's commitment to further expansion in the life sciences and biopharma markets, addressing clinical, research, and education sectors.

Key Points: 
  • CONCORD, Mass., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Dr. Carl Barrett steps into a new role as Chief Life Sciences Officer at Corista, a leader in digital image management solutions.
  • His background and experience are perfectly positioned to help us better serve digital image management needs of the medical and life sciences markets," said Corista CEO Liz Wingard.
  • Dr. Barrett brings over three decades of experience in translational research to Corista.
  • Prior to joining Corista, Dr. Barrett was Vice President of Translational Medicine and Oncology Biomarker Development in Oncology Research and Development at AstraZeneca Pharmaceuticals.

Caraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD

Retrieved on: 
Wednesday, March 2, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Lists of diseases, Janelia Research Campus, National Academy of Medicine, Harvard Medical School, Ion, Patient, Aldo, Max Planck Society, Research, Max Planck Institute for Experimental Medicine, Bardet–Biedl syndrome, Doctor of Philosophy, Emory University School of Medicine, Hospital, PKD, Coronavirus Scientific Advisory Board (Turkey), Investment, Therapy, Neuroscience, Neurodegeneration, Nobel Prize, Company, BBS, Biophysical chemistry, Polycystic kidney disease, Nephronophthisis, Internal medicine, SAB, Howard Hughes Medical Institute, HHMI, National academy, National, Pharmaceutical industry, Brigham, Caraway, MD

Caraway Therapeutics today announced the appointment of David Clapham, MD, PhD, to the companys Scientific Advisory Board (SAB).

Key Points: 
  • Caraway Therapeutics today announced the appointment of David Clapham, MD, PhD, to the companys Scientific Advisory Board (SAB).
  • I am delighted to welcome Dr. Clapham to Caraway as a scientific advisor, said Martin D. Williams, Chief Executive Officer at Caraway Therapeutics.
  • The combined cutting-edge expertise and wisdom David provides will be a key asset for Caraway as we continue to advance our programs.
  • Dr. Clapham joins Caraways experienced, collaborative, and dedicated Scientific Advisory Board team comprised of tenured biologists and biotech leaders.

PharmaBlock Appoints Dr. Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs

Retrieved on: 
Wednesday, February 16, 2022
Columbia University, University of Pennsylvania, GSK, CEO, CMC, Department, Analytic, Solution, Quality, Biophysical chemistry, Memorial, Doctor of Philosophy, Procter & Gamble, CDMO, Pharmacokinetics, Quality control, Drug discovery, University, Memorial Sloan Kettering Cancer Center, Drug development, Proctor, Medical device, Chemistry, EU, Telavancin, Titan

NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr.Zhengtian (Titan) Guas Senior Vice President of Quality and Regulatory Affairs, responsible for corporate quality management and regulatory affairs.

Key Points: 
  • NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr.Zhengtian (Titan) Guas Senior Vice President of Quality and Regulatory Affairs, responsible for corporate quality management and regulatory affairs.
  • Dr. Gu has more than 20 years of R&D and management experience in pharmaceutical development.
  • Prior to joining PharmaBlock, Dr. Gu served as Vice President of Analytical Development & Quality Control at Theravance, spearheading critical efforts for new drug development and management.
  • "Dr. Gu has deep understanding of the quality management and regulatory affairs of new drug development, especially with many years of experience in global drug R&D companies.

BiondVax Announces Proposed Underwritten Public Offering of American Depositary Shares

Retrieved on: 
Friday, December 24, 2021
U.S. Securities and Exchange Commission, Nasdaq, Omicron, Sale, Max Planck Society, Form, Humanitarian use licenses, No, Prospectus, Infection, Delta, Risk, Telephone, BVXV, Securities Act of 1933, Seventh Avenue, Attention, American depositary receipt, MPG, Private Securities Litigation Reform Act, BiondVax, SEC, COVID-19, Securities Exchange Act of 1934, UMG, Phrase, Company, Research, Nature, Biophysical chemistry, Pharmaceutical industry, Security (finance)

JERUSALEM, Dec. 23, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it intends to offer its American Depositary Shares ("ADSs") in an underwritten public offering.

Key Points: 
  • JERUSALEM, Dec. 23, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it intends to offer its American Depositary Shares ("ADSs") in an underwritten public offering.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Aegis Capital Corp. is acting as the sole book-running manager for the offering.
  • BiondVax undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany

Retrieved on: 
Wednesday, December 22, 2021
Annual report, Technology, Max, BVXV, COVID-19, Clinical trial, U.S. Securities and Exchange Commission, Drug development, Risk, Patient, Max Planck Society, Infection, Organic compound, EIB, Company, Antibody, Severe acute respiratory syndrome coronavirus 2, Multimedia, Biophysical chemistry, The EMBO Journal, Marketing, Compugen (Israeli company), Therapy, Asthma, Macular degeneration, UMG, Security (finance), GMP, Flávio Kenup, Molecular oncology, Nasdaq, European Investment Bank, Omicron, Psoriatic arthritis, Max Planck Institute for Biophysical Chemistry, University Medical Center, Coronavirus, Inhalation, CEO, Psoriasis, MPG, BiondVax, Pharmaceutical industry, Vaccine, Sanofi, Alpha, Delta

Given the potential of additional emerging VoCs, the BiondVax-MPG-UMG collaboration covers development of new NanoAbs as needed during the evolution of COVID-19.

Key Points: 
  • Given the potential of additional emerging VoCs, the BiondVax-MPG-UMG collaboration covers development of new NanoAbs as needed during the evolution of COVID-19.
  • BiondVax is planning a rapid development path that leverages the company's expertise and capabilities in biological drug development and manufacturing.
  • The technology is a great fit to our manufacturing site in Jerusalem and our experience and expertise in biological drug development.
  • Professor Dirk Grlich, Director at the Max Planck Institute for Biophysical Chemistry, commented, "We believe that the innovative platform developed at the Max Planck Institute for Biophysical Chemistry and the University Medical Center of Gttingen has great potential to provide patients with superior therapies.

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Retrieved on: 
Wednesday, December 1, 2021
University College Dublin, Cell, Company, GBM, Doctor of Philosophy, VP, SVP, DNA, Master of Science, Board, United States Air Force Scientific Advisory Board, Mannose, Glioblastoma, Genetics, Pharmacology, Prostate Cancer Foundation, Novo Holdings A/S, Cancer, University, CDO, Research, Seagen, ADC, Copenhagen, Osteosarcoma, II, Fred Hutchinson Cancer Research Center, Finsen Laboratory, CMC, Health Canada, Novo Nordisk, Soft-tissue sarcoma, Kinetics, FDA, Genmab, Brentuximab vedotin, Control, Drug discovery, Patient, CTO, Rigshospitalet, Biophysical chemistry, Industry, MAA, SAB, BLA, Program, Mesothelioma, EUR, Antibody, Science, Fine chemical, Pharmaceutical industry

In addition, Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).

Key Points: 
  • In addition, Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).
  • Commenting on the appointments, Michael Pehl, Chief Executive Officer of Adcendo, said: "I am delighted to announce these appointments today as we build on our committed team at Adcendo.
  • "We are also extremely excited to have gained someone of Dennis' caliber to support Adcendo.
  • In addition to this program, Adcendo aims to build a pipeline of additional novel cancer targets ideally suited to ADC approaches.

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Retrieved on: 
Wednesday, December 1, 2021
University College Dublin, Cell, Company, GBM, Doctor of Philosophy, VP, SVP, DNA, Master of Science, Board, United States Air Force Scientific Advisory Board, Mannose, Glioblastoma, Genetics, Pharmacology, Prostate Cancer Foundation, Novo Holdings A/S, Cancer, University, CDO, Research, Seagen, ADC, Copenhagen, Osteosarcoma, II, Fred Hutchinson Cancer Research Center, Finsen Laboratory, CMC, Health Canada, Novo Nordisk, Soft-tissue sarcoma, Kinetics, FDA, Genmab, Brentuximab vedotin, Control, Drug discovery, Patient, CTO, Rigshospitalet, Biophysical chemistry, Industry, MAA, SAB, BLA, Program, Mesothelioma, EUR, Antibody, Science, Fine chemical, Pharmaceutical industry

COPENHAGEN, Denmark, Dec. 1, 2021 /PRNewswire/ -- Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announced today the appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO) and Pernille Høyrup Hemmingsen, PhD, as Chief Technology Officer (CTO). In addition, Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).

Key Points: 
  • In addition, Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).
  • Commenting on the appointments, Michael Pehl, Chief Executive Officer of Adcendo, said: "I am delighted to announce these appointments today as we build on our committed team at Adcendo.
  • "We are also extremely excited to have gained someone of Dennis' caliber to support Adcendo.
  • In addition to this program, Adcendo aims to build a pipeline of additional novel cancer targets ideally suited to ADC approaches.